Allergan Plc reported a better-than-expected quarterly profit on strong demand for Botox

Allergan’s shares were marginally up before the bell. The company lost nearly a fifth of its value last year. In comparison, the wider S&P 500 healthcare index rose 20 percent.

Allergan Plc on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study.

The key data could ease some investor concern at a time when Allergan faces the threat of competition from generic drugmakers, reports Reuters.

Allergan’s shares were marginally up before the bell. The company lost nearly a fifth of its value last year. In comparison, the wider S&P 500 healthcare index rose 20 percent.

Botox sales jumped nearly 17 percent to $864.3 million in the fourth quarter ended Dec. 31, above consensus estimates of $778.20 million, according to Thomson Reuters I/B/E/S. Sales of dry-eye drug Restasis rose nearly 1 percent to $414.9 million, ahead of estimates of $388.6 million.

Allergan said on Tuesday that patients on its migraine treatment were relieved of pain after two hours and did not experience migraine symptoms compared to a placebo, meeting the main goals of the first of two late-stage studies.

The Dublin, an Ireland-based company, which is expected to report data from the second trial in the first half of 2018, said it would file for a marketing application for the migraine drug, ubrogepant, next year.

Ubrogepant belongs to a class of migraine drugs being developed by rivals such as Eli Lilly, Amgen and Alder Biopharmaceuticals that target a protein associated with pain signaling called CGRP.

Allergan said on Tuesday it recorded a gain of about $2.8 billion in the fourth quarter ended Dec. 31, related to recent changes to the U.S. tax law, helping it post a profit after six straight quarters of loss.

Net profit attributable to shareholders was $3.05 billion, or $8.88 per share, in the quarter, compared with a loss of $70.2 million, or $0.20 per share, a year earlier.

Excluding items, the company earned $4.86 per share, beating the average analyst estimate of $4.74. Net revenue rose 12 percent to $4.33 billion, above analysts’ estimates of $4.28 billion.

The company also forecast 2018 adjusted profit per share in the range of $15.25 to $16.00. Analysts on average were expecting $15.50.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Exclusive Immigration Offers come to Bangladesh
Samsung Bangladesh announced exciting offers at Dhaka International Trade Fair 2019
Le Méridien Dhaka brings Pitha Fest
Hyundai and Kia to invest in UK electric vehicle startup Arrival Ltd
Jeff Bezos announced a major investment in India

Advertisement

News of the Month

February 2018
S M T W T F S
« Jan   Mar »
 123
45678910
11121314151617
18192021222324
25262728  
Scroll Up
%d bloggers like this: